Please wait while the formulary information is being retrieved.
BIMZELX (bimekizumab-bkzx)
- moderate to severe plaque psoriasis
160 mg/mL subcutaneous syringe
- Inject 320 mg as 2 separate 160 mg injections by subcutaneous route every 8 weeks
Default screening record
- Inject 320 mg as 2 separate 160 mg injections by subcutaneous route every 4 weeks for 5 doses at weeks 0, 4, 8, 12, and 16 of treatment
- Inject 320 mg as 2 separate 160 mg injections by subcutaneous route every 8 weeks
- Inject 2 milliliters (320 mg) as 2 separate 160 mg injections by subcutaneous route every 4 weeks for 5 doses at weeks 0, 4, 8, 12, and 16 of treatment
- Inject 2 milliliters (320 mg) as 2 separate 160 mg injections by subcutaneous route every 8 weeks
- Inject 2 milliliters (320 mg) as 2 separate 160 mg injections by subcutaneous route every 4 weeks (for patients weighing greater than or equal to 120 kg)
- Inject 320 mg as 2 separate 160 mg injections by subcutaneous route every 4 weeks (for patients weighing greater than or equal to 120 kg)
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- natalizumab
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- tofacitinib
- typhoid vaccine
- Tysabri
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- Xeljanz
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- None
Severe
Moderate
- None
- Active tuberculosis
Contraindicated
- Depression
- Inactive tuberculosis
- Infection
- Inflammatory bowel disease
- Suicidal ideation
Severe
Moderate
- Abnormal hepatic function tests
BIMZELX (bimekizumab-bkzx)
- moderate to severe plaque psoriasis
- None
- Oral candidiasis
- Pharyngitis
- Upper respiratory infection
More Frequent
Severe
Less Severe
- Candidiasis
- Acne vulgaris
- Dermatophytosis
- Eczema
- Fatigue
- Folliculitis
- Gastroenteritis
- Headache disorder
- Herpes simplex infection
- Infection of ear
- Injection site erythema
- Injection site inflammation
- Injection site pain
- Oropharyngeal candidiasis
- Skin inflammation
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Hypersensitivity drug reaction
- Inflammatory bowel disease
- Suicidal ideation
Less Severe
- Abnormal hepatic function tests
- Acute bacterial otitis media
- Conjunctivitis
- Cutaneous candidiasis
- Neutropenic disorder
- Otitis externa
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Bimekizumab
Safety and effectiveness not established in pediatric patients < 18 years.
- 1 Day – 18 Years
- Safety and effectiveness not established in pediatric patients < 18 years.
Bimekizumab
- Severity Level:
2
- Additional Notes: Insuff human data avail; consider maternal benefit vs neonatal risk
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Bimekizumab
Insuff human data; human igg secreted into human milk
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insuff human data; human igg secreted into human milk |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Bimekizumab
Skin-elderly patients may be more likely to experience oral candidiasis, dermatitis and eczema compared to younger patients
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | N | N | N | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- None
| Moderate to severe plaque psoriasis | |
| L40.0 | Psoriasis vulgaris |
| L40.8 | Other psoriasis |
| L40.9 | Psoriasis, unspecified |
| 0-9 | A-Z |
|---|---|
| L40.0 | Psoriasis vulgaris |
| L40.8 | Other psoriasis |
| L40.9 | Psoriasis, unspecified |
Formulary Reference Tool